Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azacitidine
Drug ID BADD_D00194
Description A pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
Indications and Usage For treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.
Marketing Status Prescription
ATC Code L01BC07
DrugBank ID DB00928
KEGG ID D03021
MeSH ID D001374
PubChem ID 9444
TTD Drug ID D09FAZ
NDC Product Code 43598-678; 59572-740; 16729-306; 71288-115; 16714-927; 0781-3253; 43598-305; 71288-153; 63592-1800; 68001-313; 63759-0015; 67457-254; 59572-730; 70121-1237; 68001-527; 72606-558; 69097-805; 69097-368; 0781-9253; 59572-102; 64679-096; 68554-0104; 66529-0013; 63660-0010; 14096-121; 51991-797; 42385-719; 63323-771; 51916-350; 68001-504; 65129-1222; 72485-201; 43598-465; 53183-4011; 0143-9606; 43817-906; 54893-0029
Synonyms Azacitidine | 5-Azacytidine | 5 Azacytidine | Azacytidine | Vidaza | NSC-102816 | NSC 102816 | NSC102816
Chemical Information
Molecular Formula C8H12N4O5
CAS Registry Number 320-67-2
SMILES C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypophosphataemia14.04.03.0010.001066%
Hypotension24.06.03.002--
Hypovolaemia14.05.05.0020.000533%Not Available
Hypoxia22.02.02.0030.005328%
Ileus07.13.01.0010.001066%
Immune system disorder10.02.01.0010.001066%Not Available
Infection11.01.08.0020.014039%Not Available
Infective myositis15.05.01.003; 11.01.17.0010.000533%
Inflammatory bowel disease07.08.01.0160.000533%Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Influenza like illness08.01.03.010--
Inguinal hernia07.16.02.0010.001066%Not Available
Injection site bruising24.07.06.017; 23.03.11.015; 12.07.03.042; 08.02.03.042--Not Available
Injection site dermatitis23.03.04.033; 12.07.03.041; 08.02.03.041--Not Available
Injection site erythema23.03.06.015; 08.02.03.001; 12.07.03.001--Not Available
Injection site granuloma23.03.15.003; 12.07.03.003; 08.02.03.003--Not Available
Injection site haematoma24.07.01.009; 12.07.03.004; 08.02.03.004--Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.005--Not Available
Injection site induration12.07.03.007; 08.02.03.007--Not Available
Injection site infection12.07.03.008; 11.01.08.005; 08.02.03.019--Not Available
Injection site necrosis12.07.03.020; 08.02.03.020--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site pruritus08.02.03.013; 23.03.12.007; 12.07.03.014--Not Available
Injection site rash23.03.13.010; 12.07.03.032; 08.02.03.032--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia17.15.03.002; 19.02.01.002--
Interstitial lung disease10.02.01.033; 22.01.02.0030.010656%Not Available
Intestinal obstruction07.13.01.0020.002398%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Joint swelling15.01.02.004--Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 24 Pages